Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 174-180

  Solomayer, Erich Franz ^a   Feuerer, Markus ^b   Bai, Lianhua ^b   Umansky, Victor ^b   Beckhove, Philipp ^b   Meyberg, Gabriele C ^a   Bastert, Gunther ^c   Schirrmacher, Volker ^b   Diel, Ingo Jakob ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; TAMOXIFEN;

ADULT; ARTICLE; BLOOD; BONE MARROW; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL MEMORY; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD56; ANTIGENS, CD8; BONE MARROW CELLS; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HORMONES; HUMANS; IMMUNOPHENOTYPING; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, NATURAL; MACROPHAGES; MONOCYTES; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES;

EID: 12244294476     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Karrison, T., Ferguson, D., and Meier, P. Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. (Bethesda), 91: 80-85, 1999.
2. Orr, F., Kostenuik, P., Sanchez-Sweatman, O., and Singh, G. Mechanism involved in the matastasis of cancer to bone. Breast Cancer Res. Treat., 25: 151-163, 1993.
3. Braun, S., Pantel, K., Muller, P., Janni, W., Hepp, F., Kentenich, C., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., Riethmuller, G., and Schlimok, G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I. II or III breast cancer. N. Eng. J. Med., 342: 525-533, 2000.
4. Solomayer, E-F., Diel, I. J., Salanti, G., Hahn, M., Gollan, C., Schütz, F., and Bastert, G. Time independency of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin. Cancer Res., 7: 4102-4108, 2001.
5. Diel, I., Kaufmann, M., Costa, S., Holle, R., von Minckwitz, G., Solomayer, E., Kaul, S., and Bastert, G. Micrometastatic breastv cancer cells in bone marrow at primary surgery-prognostic value in comparison with nodal status. J. Natl. Cancer Inst. (Bethesda), 88: 1652-1658, 1996.
6. Mansi, J., Gogas, H., Bliss, J., Gazet, J., Berger, U., and Coombes, R. Outcome of primary breast cancer patients with micrometastases: a long term follow-up study. Lancet, 354: 197-202; 1999.
7. Von Mensdorrf-Pouilly, S., Verstraeten, A. A., Kenemans, P., Snijdewint, F. G., Kok, A., Van Kamp, G. J., Paul, M. A., Van Diest, P. J., Meijer, S., and Hilgers, J. Survival in early breast cancer patients is favourably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol., 18: 547-582, 2000.
8. Mccoy, J. L., Rucker, R., and Petros, J. A. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade, or lymph node status. Breast Cancer Res., 60: 227-234, 2000.
9. Chen, Y., Scanlan. M., Sahin, U., Tureci, O., Gure, A., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. A. testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.
10. Scanlan, M., Chen, Y., Williamson, B., Gure, A., Stockert, E., Gordan, J., Tureci, O., Sahin, U., Pfreundschuh, M., and Old, L. Characterization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer., 76: 652-658, 1998.
11. Valmori, D., Dutoit, V., Lienard, D., Lejeune, F., Speiser, D., Rimoldi, D., Cerundolo, V., Dietrich, P., Cerottini, J., and Romero, P. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J. Immunol., 165: 533-538, 2000.
12. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, J., Greenberg, P. D., Roederer, M., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-658, 1999.
13. Valmori, D., Dutoit, V., Lienard, D., Rimoldi, D., Pittet, M. J., Champagne, P., Ellefsen, K., Sahin, U., Speiser, D., Lejeune, F., et al. Naturally occurring human lymphocyte antigen A2 restricted CD8 T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res., 60: 4499-4506, 2000.
14. Feuerer, M., Rocha, M., Bai, L., Umansky, V., Solomayer, E. F., Bastert, G., Diel, I. J., and Schirrmacher, V. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer, 92: 96-105, 2001.
15. Feuerer, M., Beckhove, P., Bai, L., Solomayer, E., Bastert, G., Diel, I., Pedain, C., Obemiedermayr, M., Schirrmacher, V., and Umansky, V. Therapy of human tumors in NOD/SCID mice with patient derived reactivated memory T cells from bone marrow. Nat. Med., 7: 452-458, 2001.
16. Kruger, W., Krzizanowski, C., Holweg, M., Stockschlager, M., Kroger, N., Jung, R., Mross, K., Jonat, W., and Zander, A. R. Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J. Cancer Res. Clin. Oncol., 122: 679, 1996.
17. Shih, W., Baumhefner, R., Tourtellotte. W., Haskelle, C., Korn, E., and Fahey, J. Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin. Exp. Immunol., 53: 122-132, 1983.
18. Allison, A. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 47: 63-83, 2000.
19. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., and Revillard, J. P. Immunosuppressive properties of methotrexate:apoptosis and clonal deletion of activated peripheral t cells. J. Clin. Investig., 102: 322-328, 1998.
20. Ciaiolo, C., Ferrero, D., Pugliese, A., Biglino, A., Marletto, G., Tonello, M., Colzani, G., and Marietti, G. Enhancement of methotrexate cytotoxicity by modulation of proliferative activity in normal and neoplaqstic t lymphocytes and in a myeloid cell line. Tumori, 74: 537-542, 1988.
21. Ben-Efraim, S., Shoval, S., and Ophir, R. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer Immunol. Immunother., 22: 43-48, 1986.
22. Hakim, F., Cepeda, R., Kaimei, S., Mackall, C., McAtee, N., Zujewski, J., Cowan, K., and Gress, R. Constraints on CD4 recovery post chemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood, 90: 3789-3798, 1997.
23. Mackall, C., Fleisher, T., Brown, M., Magrath, I., Shad, A., Horowitz, M., Wexler, L., Adde, M., McClure, L., and Gress, R. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood, 84: 2221-2228, 1994.
24. Murta, E. F., De Andrade. J. M., Falcao, R. P., and Bighetti, S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori, 86: 403-407, 2000.
25. Brunvand, M. W., Collins, C., Livingston, R. B., and Raghu, G. Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-subset ratios during treatment for early-stage breast carcinoma. Cancer (Phila.), 67: 2407-2409, 1991.
26. Avigan, D., Wu, Z., Joyce, R., Elias, A., Richardson, P., McDermott, D., Levine, J., Kennedy, L., Giallombardo, N., Hurley, D., Gong, J., and Kufe, D. Immune reconstitution following high dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant., 26: 169-176, 2000.
27. Frank, M., Denton, M., Alexander, S., Khoury, D., Sayegh, M., and Briscoe, D. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J. Immunol., 166: 2451-2459, 2001.
28. Baral, E., Nagy, E., Kwok, S., McNicol, A., Gerrard, J., and Berczi, I. Supression of lymphocyte mitogenesis by tamoxifen: studies on protein kinase C, calmodulin and calcium. Neuroimmunomodulation, 7: 68-76, 2000.
29. Wu, W., Lin, B. F., Su, Y. C., Suen, J. L., and Chiang, B. L. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand. J. Immunol., 52: 393-400, 2000.
30. Mor, G., Kohen, F., Garcia-Velasco, J., Nilsen, J., Brown, W., Song, J., and Naftolin, F. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J. Steroid Biochem. Mol. Biol., 73: 185-194, 2000.
31. Sabbioni, M. E., Castiglione, M., Hurny, C., Siegrist, H. P., Bacchi, M., Bernhardd, J., Thurlimann, B., Bonnefoi, H., Perey, L., Goldhirsch, A., and Senn, H. J. Interaction of tamoxifen with concurrent cytotoxic adjuvant reatment affects lymphocyte subsets counts in breast cancer patients. Support Care Cancer, 7: 149-153, 1999.
32. Osmond, D. Production and selection of B lymphocytes in bone marroe: lymphostromal interactions and apoptosis in normal, mutant and transgenic mice. Adv. Exp. Med. Biol., 355: 15-20, 1994.
33. Koni, P. A., Joshi, S. K., Temann, U. A., Olson, D., Burkly, L., and Flavell, R. A. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J. Exp. Med., 193: 741-753, 2001.
34. Crocker, P., and Gordon, S. Isolation and characterization of resident stromal macrophages and hematopoietic cell clusters from mouse bone marrow. J. Exp. Med., 162: 993-1014, 1985.
35. Norbury, C. C., Hewlett, L. J., Prescott, A. R., Shastri, N., and Watts, C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity, 3: 783-791, 1995.
36. Lenz, L., Butz, E., and Bevan, J. Requirements for bone marrow-derived antigen presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med., 192: 1135-1142, 2000.
37. Khazaie, K., Prifti, S., Beckhove, P., Griesbach, A., Russel, S., Collins, M., and Schirrmacher, V. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long term immunological protection. Proc. Natl. Acad. Sci. USA, 91: 7430, 1994.